重组人促红细胞生成素治疗化疗相关性贫血的临床研究

The clinical study on recombinant human erythropoietin for chemotherapy-related anemia

目的:探讨重组人促红细胞生成素(recombinant human erythropoietin,rhEPO)治疗化疗相关性贫血的临床疗效。方法:将62例肿瘤相关性贫血患者按化疗时间顺序分成治疗组和对照组,治疗组接受2个周期的化疗,并于每1个周期化疗结束48h后给予rhEPO 12000u皮下注射,3次/周,连续3周,共用6周。对照组仅接受2个周期的化疗。2组的辅助治疗相同。于第2个周期的rhEPO治疗结束后评价疗效。结果:rhEPO治疗6周后,治疗组的血红蛋白水平、血细胞比容较治疗前有明显上升,差异有统计学意义(P<0.01);患者的疲劳感减轻、活动耐力提高,与对照组相比,差异有统计学意义(P<0.01)。对照组化疗前后血红蛋白水平、血细胞比容的变化不明显。结论:rhEPO能改善化疗相关性贫血,提高肿瘤患者的生活质量。

Objective：To investigate the therapeutic effect of recombinant human erythropoietin （rhEPO） on chemotherapy- related anemia in clinic. Methods： Sixty-two tumor patients were randomly divided into treatment group and control group. Treatment group received 2 cycles of chemotherapy and subcutaneous injection of rhEPO 12 000 u at 48 h after termination of chemotherapy （thrice per week for 3 weeks, totally 6 weeks）. Control group only received 2 cycles of chemotherapy. The adjuvant therapy was the same in the two groups. The clinical efficacy was evaluated at the end of the 2nd cycle of rhEPO therapy. Results： The levels of hematoglobin and hematocrit were increased obviously after 6-week rhEPO treatment. The difference was significant （ P 〈 0.01 ）. The symptom of fa- tigue was relieved, and the active endurance was raised. Significant difference was observed between the treatment group and the control group （ P 〈0.01 ）. The levels of hemoglobin and hematocrit had no significant changes after treatment in the control group. Conclusion： rhEPO ameliorated chemotherapy-related anemia and increased the life quality of tumor patients.